Dr. Catherine J. Pointon, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- New York Medical College (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,033
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: New York Medical College
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
NC license 9701848 -
Specialist
NC license 9701848
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Piedmont Plastic Surgery and Dermatology PA (56 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,033
- Services billed
- 4,607
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 1,044 | 753 |
| Biopsy of related skin growth, first growth | 643 | 504 |
| Destruction of precancer skin growth, 1 growth | 481 | 353 |
| Destruction of precancer skin growth, 2-14 growths | 406 | 156 |
| Biopsy of related skin growth, each additional growth | 321 | 197 |
| Established patient office or other outpatient visit, 30-39 minutes | 230 | 165 |
| Established patient office or other outpatient visit, 10-19 minutes | 217 | 183 |
| Destruction of skin growth, 1-14 growths | 168 | 149 |
| Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | 64 | 50 |
| New patient office or other outpatient visit, 30-44 minutes | 63 | 63 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 19 payments worth $377 in total to this clinician.
| AbbVie Inc. | $110 |
|---|---|
| Janssen Biotech, Inc. | $77.91 |
| Genzyme Corporation | $57.97 |
| Botanix Sb Inc | $44.35 |
| E.r. Squibb & Sons, L.l.c. | $41.96 |
| Mayne Pharma Commercial LLC | $25.26 |
| Galderma Laboratories, L.P. | $19.15 |
| Food and Beverage | $377 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $42,690 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
AbbVie Inc. · Active, not recruiting · NCT05889182 - M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (St…
AbbVie Inc. - A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
Incyte Corporation - A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company · Recruiting · NCT05723198 - Psosa (psoriasis special areas) - a us-based, single-arm, prospective, multicenter, observational study of nail and scalp psoriasis improvement in patients treated with ixekizumab
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.